drugset / Trial / NCT02710604
Phase 2, Multiple Ascending Dose Proof of Concept Study
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.
Timeline
- Start
- 2016-05
- Primary completion
- 2017-07-18
- Completion
- 2017-07-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TDF | Unknown | 300 mg | — |
| Comparator | Tenofovir Exalidex | Other / unclassified | 5 mg | Oral |
| Comparator | Tenofovir Exalidex | Other / unclassified | 10 mg | Oral |
| Comparator | Tenofovir Exalidex | Other / unclassified | 25 mg | Oral |
| Comparator | Tenofovir Exalidex | Other / unclassified | 50 mg | Oral |
| Comparator | Tenofovir Exalidex | Other / unclassified | 100 mg | Oral |